CDK5 and cancer: Inhibition of CDK5 elevated the expression of FBXO22 and subsequently inhibited PD-L1 protein levels, indicating that CDK5 was an upstream regulator of FBXO22 and that CDK5 inhibitors could increase the efficacy of immunotherapy in cancer cells (47).